Edition:
United States

Biomerieux SA (BIOX.PA)

BIOX.PA on Paris Stock Exchange

187.00EUR
29 May 2017
Change (% chg)

-- (--)
Prev Close
€187.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
30,252
52-wk High
€191.10
52-wk Low
€109.00

Latest Key Developments (Source: Significant Developments)

Biomerieux Q1 Consolidated sales rise to 568 million euros
Thursday, 20 Apr 2017 01:24am EDT 

April 20 (Reuters) - Biomerieux SA ::Consolidated sales rose to 568 million euros ($609.18 million) for the first three months of 2017, up from 489 million euros in the same period one year earlier.  Full Article

Biomerieux receives FDA 510(k) clearance for BacT/ALERT VIRTUO fully automated blood culture system
Thursday, 6 Apr 2017 01:00am EDT 

Biomerieux Sa :Biomerieux receives FDA 510(k) clearance for its BacT/ALERT VIRTUO fully automated blood culture system.  Full Article

Biomerieux FY sales up 7.1 pct as reported at 2.10 billion euros
Wednesday, 1 Mar 2017 01:09am EST 

Biomerieux Sa : Board of directors will recommend that shareholders at annual meeting on May 30 approve a dividend of 1.00 euros per share . FY sales 2.10 billion euros ($2.22 billion) versus 1.97 billion euros year ago . 2017 objectives: . organic growth in sales of between 8 pct and 9 pct . Dividend is unchanged from dividend paid previous year . FY earnings per share 4.54 euros versus 2.80 euros year ago . Dividend would represent a total payout of 39.5 million euros, to be paid on June 8, 2017. . 2017 objectives: contributive operating income before non-recurring items of between 300 million euros and 315 million euros .FY operating income 282 million euros versus 195 million euros year ago.  Full Article

Biomerieux launches first FDA-cleared procalcitonin assay
Friday, 24 Feb 2017 01:00am EST 

Biomerieux SA :Biomérieux’s VIDAS BRAHMS PCT becomes the first FDA-cleared procalcitonin assay as an aid for antibiotic stewardship in respiratory infections and sepsis.  Full Article

FDA clears test to help manage antibiotic treatment for lower respiratory tract infections and sepsis
Thursday, 23 Feb 2017 05:41pm EST 

Biomerieux Sa : U.S. FDA clears test to help manage antibiotic treatment for lower respiratory tract infections and sepsis . U.S. FDA - cleared expanded use of Vidas Brahms percent assay to help manage antibiotic treatment for lower respiratory tract infections and sepsis .U.S. FDA - Vidas Brahms test is manufactured by Biomérieux Inc.  Full Article

Biomerieux 2016 sales up at 2,103 million euros
Thursday, 19 Jan 2017 01:01am EST 

Biomerieux SA : Remarkable growth in sales in 2016, up 9.6 pct like-for-like, lifted by all regions and all strategic lines . Consolidated sales amounted to 2,103 million euros ($2.24 billion) in 2016, versus 1,965 million euros in 2015 .For FY, expects contributive operating income before non-recurring items to be slightly above its previous target, moving closer to 300 million euros.  Full Article

Biomerieux and Banyan Biomarkers partner to develop, validate and market blood-based biomarkers for traumatic brain injury
Thursday, 19 Jan 2017 01:00am EST 

Biomerieux SA : Biomerieux and Banyan Biomarkers partner to develop, validate and market blood-based biomarkers for traumatic brain injury . Under terms of agreement, Biomerieux takes equity participation of about $7 million in Banyan Biomarkers . Obtains rights to commercialize Banyan's proprietary tests worldwide for use in in vitro diagnostics, with preferred rights for its Vidas Immunoassays range .In addition, two companies will continue to explore co-development opportunities in area of TBI and critical care.  Full Article

Biomerieux introduces Evisight Compact
Thursday, 6 Oct 2016 01:00am EDT 

Biomerieux SA :Biomerieux introduces Evisight Compact, a new automated diagnostic solution for microbial detection in pharmaceutical production.  Full Article

Biomerieux 2016 guidance revised to top of range
Wednesday, 31 Aug 2016 01:00am EDT 

Biomerieux SA : H1 net income of consolidated companies 86 million euros ($95.9 million) versus 59 million euros a year ago . 2016 financial targets revised . 2016 organic sales growth could end year at or above higher end of previously targeted 6.0 pct to 8.0 pct range . FY contributive operating income before non-recurring items expected to come in at around the top of the initially targeted 265 million euros to 290 million euros range . Consolidated net debt amounted to 265 million euros at June 30, 2016 versus 219 million euros at December 31, 2015 .H1 operating income 146 million euros versus 103 million euros year ago.  Full Article

Biomerieux H1 sales up 10.9 pct, at constant exchange rates and scope of consolidation
Monday, 18 Jul 2016 01:00am EDT 

Biomerieux SA : Strong growth in sales, up 10.9 pct, at constant exchange rates and scope of consolidation in first half of 2016 .H1 sales reached 1,001 million euros ($1.11 billion).  Full Article

More From Around the Web

BRIEF-Chairman Mustafa Latif Topbas transfers 14.78 pct stake in BIM to Merkez Bereket Gida-KAP

* CHAIRMAN MUSTAFA LATIF TOPBAS TRANSFERS HIS 14.78 PCT DIRECT STAKE IN BIM TO MERKEZ BEREKET GIDA AT 61.0 LIRA PER SHARE-KAP